Naba Alsaha Medical Services Co. (9546) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Naba Alsaha Medical Services Co. stock SAR 23.53, price SAR 21.98, upside +7.1%, quality 43 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.
How to read this chart
49‑month range 13.74 SAR – 1,000,000 SAR · fair‑value band 16.58 SAR – 30.63 SAR · the 21.98 SAR price screens below the 23.53 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.
Follow Naba Alsaha Medical Services Co. in your weekly email
Every Wednesday you see whether Naba Alsaha Medical Services Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Naba Al Saha Medical Services Company operates private and governmental hospitals, and health facilities in the Kingdom of Saudi Arabia. It owns, operates, and manages Al-Zahraa Hospital, Manarat Al-Haramain Pharmacy, and Nab'a Al-Sahah branch.
Show moreShow less
The company provides outpatient, inpatient, clinics, and operation services; emergency and intensive care services; maintenance of electromechanical systems; maintenance and cleaning services; and building operation services.
It is involved in construction and maintenance of medical facilities; provision of strategic consulting; training of medical and administrative personnel; development of therapeutic programs and medical services; quality management; and pharmacy operation, as well as operates hospital.
The company was founded in 1984 and is based in Al Khobar, the Kingdom of Saudi Arabia.
Stock analysis
Naba Alsaha Medical Services Co. (9546) currently trades at 21.98 SAR, while our model-based Fair Value estimate is 23.53 SAR, so the stock looks roughly fairly valued today (gap 6.6%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 23.68 SAR per share, and 6 of the 16 models we run sit above the 21.98 SAR price.
Bear case: the Economic Profit group reads lowest at 5.02 SAR, and 10 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: 16.58 SAR (bear) to 30.63 SAR (bull), the price of 21.98 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Naba Alsaha Medical Services Co. reported revenue of 202M SAR in FY2025 versus 118M SAR in FY2021, a compound +14.4%/yr. Reported net income was 27.5M SAR in FY2025, compounding +1.6%/yr from FY2021.
Key figures
Market cap 472M SAR (≈ $126M) Micro · P/E ratio 16.2 · P/S ratio 2.24 · EPS (TTM) 1.36 SAR · Dividend yield 0.7% · Net margin 13.9% · Return on equity 12.7% · Return on assets (EBIT) 13.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 7%, 9546 screens richer than that median.
Fair Value models
Bear16.58 SARFair Value 23.53 SARBull30.63 SAR
Price 21.98 SAR · Upside +7.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.13 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+1.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.9%
Dividend (yield on the price)0.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 15%
Compare Naba Alsaha Medical Services Co. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 243 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside+7.1% · Above median
Profitability
Return on equity (12 months)12.7% · Above median
Return on assets7.2% · Above median
Net margin (12 months)13.9% · Top 25%
Operating margin (12 months)14.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)4.4% · Below median
Dividend yield (12 months)0.7% · Bottom 25%
Balance sheet
Debt / equity0.54× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Naba Alsaha Medical Services Co. Fair Value". https://www.fairvalue-calculator.com/stock/9546
Frequently asked questions
Is Naba Alsaha Medical Services Co. (9546) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of 23.53 SAR versus a price of 21.98 SAR, about +7% upside (fairly valued).
What is the fair value of 9546?
Our model-based fair value for Naba Alsaha Medical Services Co. is 23.53 SAR (as of Oct 27, 2026), built from audited fundamentals. The current price: 21.98 SAR.
What is the quality score of 9546?
Naba Alsaha Medical Services Co. has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Naba Alsaha Medical Services Co. (9546)?
Our model-based price target is the fair value of 23.53 SAR (as of Oct 27, 2026) from 16 valuation models. Cautious scenario 16.58 SAR, optimistic scenario 30.63 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Naba Alsaha Medical Services Co. stock forecast for 2026?
Our models put fair value at 23.53 SAR, about +7% upside versus a price of 21.98 SAR (fairly valued). Cautious scenario 16.58 SAR, optimistic scenario 30.63 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Naba Alsaha Medical Services Co. (9546)?
Naba Alsaha Medical Services Co. reported trailing-twelve-month revenue of about 206M SAR (latest available figure, as of Oct 27, 2026).
Does Naba Alsaha Medical Services Co. pay a dividend?
Naba Alsaha Medical Services Co. currently shows a dividend yield of 0.67% relative to its recent price (as of Oct 27, 2026).
What is the intrinsic value of Naba Alsaha Medical Services Co. (9546)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Naba Alsaha Medical Services Co. it is 23.53 SAR per share (as of Oct 27, 2026), against a price of 21.98 SAR. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Naba Alsaha Medical Services Co. stock overvalued or undervalued in 2026?
As of Oct 27, 2026, 9546 trades below its calculated fair value: price 21.98 SAR, fair value 23.53 SAR, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9546?
No. The price is what the market pays today (21.98 SAR); the fair value is what the company's own numbers justify (23.53 SAR). For Naba Alsaha Medical Services Co. the two are 1.55 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Naba Alsaha Medical Services Co. worth?
The market values Naba Alsaha Medical Services Co. at about 472M SAR (market capitalisation, as of Oct 27, 2026). Per share that is 21.98 SAR; our models calculate a fair value of 23.53 SAR per share.
What do the bullish and bearish scenarios say about 9546?
Our models span a range for Naba Alsaha Medical Services Co.: cautious scenario 16.58 SAR, base 23.53 SAR, optimistic 30.63 SAR per share (as of Oct 27, 2026, price 21.98 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9546?
Naba Alsaha Medical Services Co. trades at a price-to-earnings ratio of 16.2 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 23.53 SAR is built from several models across several years. Other multiples: P/B 2.1, P/S 2.2, EV/EBITDA 13.0.
How solid is the balance sheet of Naba Alsaha Medical Services Co. (9546)?
Balance-sheet figures for Naba Alsaha Medical Services Co. (as of Oct 27, 2026): return on equity 12.7%, debt of 0.54 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 9546 from its 52-week high?
Naba Alsaha Medical Services Co. trades at 21.98 SAR, about 26% below its 52-week high of 29.85 SAR and 10% above the low of 20.06 SAR (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 23.53 SAR is for.
Which stocks are comparable to Naba Alsaha Medical Services Co.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Naba Alsaha Medical Services Co. stock attractive at the current price?
The data as of Oct 27, 2026: price 21.98 SAR, calculated fair value 23.53 SAR (+7%), Quality Score 43/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9546 calculated?
We run Naba Alsaha Medical Services Co. through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 23.53 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Naba Alsaha Medical Services Co. currently trades 7 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Naba Alsaha Medical Services Co. (9546)?
The closing price on Oct 28, 2026 was 21.98 SAR. Our model-based fair value is 23.53 SAR, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Naba Alsaha Medical Services Co. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (16.58 SAR to 30.63 SAR) leaves room in how you read the outcome.
Key figures of Naba Alsaha Medical Services Co.
How large is the market capitalisation of Naba Alsaha Medical Services Co. (9546)?
The market capitalisation of Naba Alsaha Medical Services Co. is 472M SAR (≈ $126M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Naba Alsaha Medical Services Co. (9546)?
The price-to-sales ratio of Naba Alsaha Medical Services Co. is 2.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Naba Alsaha Medical Services Co. (9546)?
Earnings per share at Naba Alsaha Medical Services Co. are 1.36 SAR (price ÷ EPS = P/E 16.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Naba Alsaha Medical Services Co. (9546)?
The dividend yield of Naba Alsaha Medical Services Co. is 0.7% (payout 10.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Naba Alsaha Medical Services Co. (9546)?
The net margin of Naba Alsaha Medical Services Co. is 13.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Naba Alsaha Medical Services Co. (9546)?
The return on equity (ROE) of Naba Alsaha Medical Services Co. is 12.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Naba Alsaha Medical Services Co. (9546)?
On an EBIT basis the return on assets of Naba Alsaha Medical Services Co. is 13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Naba Alsaha Medical Services Co. (9546)?
The operating margin of Naba Alsaha Medical Services Co. is 14.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Naba Alsaha Medical Services Co. (9546)?
Revenue at Naba Alsaha Medical Services Co. is growing +4.4% versus a year earlier (3y avg +15.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Naba Alsaha Medical Services Co. (9546)?
Earnings per share at Naba Alsaha Medical Services Co. are growing +7.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Naba Alsaha Medical Services Co. (9546) generate?
The free cash flow of Naba Alsaha Medical Services Co. is −51.2M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Naba Alsaha Medical Services Co. (9546) carry?
The net debt of Naba Alsaha Medical Services Co. is 102M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Naba Alsaha Medical Services Co. in the live analysis
One click puts Naba Alsaha Medical Services Co. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 27, 2026